Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer

Objectives: The purpose of this study was to evaluate whether immune checkpoint inhibitors (ICIs) are associated with an increased risk of major adverse cardiovascular events (MACE) compared with non-ICI therapies in patients with lung cancer. Background: ICIs activate the host immune system to targ...

Full description

Bibliographic Details
Main Authors: Kalyan R. Chitturi, DO, Jiaqiong Xu, PhD, Raquel Araujo-Gutierrez, MD, Arvind Bhimaraj, MD, Ashrith Guha, MD, Imad Hussain, MD, Mahwash Kassi, MD, Eric H. Bernicker, MD, Barry H. Trachtenberg, MD
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:JACC. CardioOncology
Subjects:
BNP
cardiotoxicity
immune checkpoint inhibitors
lung cancer
MACE
troponin
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087319301000

Internet

http://www.sciencedirect.com/science/article/pii/S2666087319301000

Similar Items